Drug intelligence / Profile preview

Borraginol

Development stage
Unknown
Lead developer
Amato Pharmaceutical Products
Modality
Small Molecules
Administration
Topical, Rectal, Oral
01

Overview

Borraginol is a comprehensive line of hemorrhoid treatments developed and marketed by Amato Pharmaceutical Products. Originally developed at Kyoto University Hospital and launched in 1921, it is a leading over-the-counter (OTC) brand in Japan for the relief of pain, bleeding, swelling, and itching associated with hemorrhoids and anal fissures. The product line is divided into the **Borraginol A** series, which includes the corticosteroid prednisolone acetate for anti-inflammatory action, and the steroid-free **Borraginol M** series. Both series typically contain lidocaine (local anesthetic), allantoin (wound healing), and vitamin E acetate (blood circulation improvement). Additionally, the brand includes **Borraginol EP Oral**, an internal medication containing herbal extracts like Moutan cortex and Rosskastanien to address hemorrhoidal symptoms from within.

Brand names
BorraginolBorraginol ABorraginol MBorraginol EP Oral
Other names
BORRAGINOL seriesBORRAGINOL ointmentsBORRAGINOL suppositoriesBORRAGINOL patchesBORRAGINOL tablets
02

Targets

NaV (Voltage-gated sodium channels)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Borraginol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Borraginol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call